Next-generation Activin x GDF ligand traps.
Overview
We are developing a pipeline of next-generation Activin x GDF ligand traps. Our lead program, HS235, is undergoing Proof-of-Principle Phase I/II clinical studies.
Program
Modality
Indication
Discovery
IND enabling
Phase 1 HV
Clinical PoC
Pivotal
HS235
Activin x GDF trap
Pulmonary Arterial Hypertension
PH-HFpEF
Obesity
HS370
Activin x GDF trap
Undisclosed
Program
HS235
Modality
Activin x GDF trap
Indication
Pulmonary Arterial Hypertension
PH-HFpEF
Obesity
Discovery
IND enabling
Phase 1 HV
Clinical PoC
Pivotal
Show more
Less
Program
HS370
Modality
Activin x GDF trap
Indication
Undisclosed
Discovery
IND enabling
Phase 1 HV
Clinical PoC
Pivotal
News
Subscribe
To receive our press releases, please subscribe to our mailing list
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.